CDEK
← All drugs Report issue

empagliflozin

Trade name: jardiance

Small moleculeapproved

Approved

Aug 1, 2014

Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor designed for the treatment of type 2 diabetes mellitus. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Empagliflozin interacts with diuretics, blood presure medicine and insulin. Jardiance reduces the risk of cardiovascular death in diabetes patients at high cardiovascular risk. — NCATS

Clinical trial activity

449 trials · 273 clinical orgs · 16 marketing orgs

Phase 1
109
Phase 2
173
Phase 3
111
Phase 4
119

Earliest trial started Jan 1, 2007 (NCT02172170)

Timeline

2000s

  1. Jan 1, 2007

    Boehringer Ingelheim — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Boehringer Ingelheim — Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Boehringer Ingelheim — Earliest Phase 3 Sponsor(trial)

  2. Aug 1, 2014

    Boehringer Ingelheim — Earliest FDA Approval

  3. Aug 1, 2014

    Boehringer Ingelheim — NDA Secondary Org

  4. Aug 1, 2014

    Boehringer Ingelheim — NDA Organization

2020s

  1. Apr 30, 2020

    Zydus Discovery DMCC — Marketing Organization

  2. Jul 7, 2020

    MSN Laboratories — Marketing Organization

  3. Aug 26, 2020

    Kinapse — Marketing Organization

  4. Aug 26, 2020

    Syneos Health — Marketing Organization

  5. Dec 29, 2020

    Aizant — Marketing Organization

  6. Jan 6, 2021

    Lupin — Marketing Organization

  7. Jan 28, 2021

    Annora Pharma — Marketing Organization

  8. Jan 20, 2022

    Prinston Inc — Marketing Organization

  9. Jun 30, 2022

    Laurus Labs Ltd — Marketing Organization

  10. Aug 9, 2022

    Alkem Labs Ltd — Marketing Organization

  11. Mar 10, 2023

    Sun Pharmaceuticals — Marketing Organization

  12. Dec 26, 2024

    Cipla — Marketing Organization

  13. Apr 11, 2025

    Ajanta Pharma Ltd — Marketing Organization

  14. Jul 16, 2025

    Macleods Pharmaceuticals, Ltd — Marketing Organization

  15. May 21, 2026

    Aurobindo Pharma — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Combination products

Approval history

  • approvedAug 1, 2014

Chemistry & pharmacology

Loading structure…

SMILES

OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=C(O[C@H]4CCOC4)C=C3)=C(Cl)C=C2
Mol. weight
450.909 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
  • 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
  • 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
  • (1s)-1,5-anhydro-1-(4-chloro-3-{4-[(3s)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-d-glucitol
  • (1s)-1,5-anhydro-1-(4-chloro-3-{4-[(3s)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-d-glucitol
  • bi10773
  • bi10773
  • bi10773
  • bi 10773
  • bi 10773
  • bi 10773
  • bi 10773
  • bi-10773
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin
  • empagliflozin (bi 10773)
  • empagliflozin / linagliptin
  • empagliflozin / linagliptin
  • empagliflozin / metformin
  • jardiance
  • jardiance
  • jardiance
  • jardiance
  • jardiance

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07060417Phase 2Apr 1, 2026Department of Veteran Affairs
NCT07304817Phase 2Feb 28, 2026Boehringer Ingelheim, University of Groningen
NCT07053319Phase 1Feb 1, 2026National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Texas, San Antonio
NCT07074418Phase 4Dec 31, 2025Boehringer Ingelheim, University of Nice Sophia Antipolis
NCT07175051Phase 2Dec 31, 2025University of Illinois at Chicago
NCT07311551Phase 4Dec 24, 2025All India Institute of Medical Sciences
NCT07107945Phase 3Dec 12, 2025Boehringer Ingelheim
NCT07228195Phase 4Dec 1, 2025University of Minnesota
NCT07055282Early Phase 1 (Phase 1)Nov 25, 2025National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), University of Chicago
NCT07214818Phase 2/Phase 3 (Phase 3)Nov 15, 2025Mansoura University
NCT07180745Phase 4Nov 1, 2025Badr University
NCT07038356Phase 3Oct 1, 2025Friedrich Schiller University
NCT07155694Phase 4Sep 30, 2025Bayer, Department of Veteran Affairs
NCT07102719Phase 1Sep 30, 2025Handok Pharmaceuticals Co., Ltd.
NCT07146880Phase 2Sep 15, 2025National Taiwan University, Stanford University
NCT07133399Phase 1Sep 8, 2025Boehringer Ingelheim
NCT07292909Phase 4Sep 1, 2025University of Paris
NCT07065357Phase 3Aug 13, 2025The University of Hong Kong
NCT07266766Phase 1Aug 5, 2025Humanis Saglık Anonim Sirketi
NCT07064473Phase 3Jul 22, 2025Boehringer Ingelheim
Showing 20 of 449 trials
Page 1 / 23

Organizations

Research & Development (273)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit13510642007
Eli LillyFor profit52052009
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government12142016
University of CopenhagenAcademic/Hospital10642016
Tanta UniversityAcademic/Hospital9852022
Chong Kun Dang PharmaceuticalFor profit7622016
Department of Veteran AffairsGovernment7742023
Seoul National UniversityAcademic/Hospital7522017
EMS S/AFor profit6612021
Free University of AmsterdamAcademic/Hospital6532017
McGill UniversityAcademic/Hospital6442018
University of BaselAcademic/Hospital6442016
University of BernAcademic/Hospital6632016
University of Texas, San AntonioAcademic/Hospital6612021
Yonsei UniversityAcademic/Hospital6432016
Humanis Saglık Anonim SirketiAcademic/Hospital5512023
National Taiwan UniversityAcademic/Hospital5422019
Novo NordiskFor profit5322016
University of TorontoAcademic/Hospital5532017
Ain Shams UniversityAcademic/Hospital4432018
273 organizations
Page 1 / 14

Marketing (18)

OrganizationOrg typeRelationshipDate
AizantFor profitMKTGDec 29, 2020
Ajanta Pharma LtdFor profitMKTGApr 11, 2025
Alkem Labs LtdFor profitMKTGAug 9, 2022
Annora PharmaFor profitMKTGJan 28, 2021
Aurobindo PharmaFor profitMKTGMay 21, 2026
Boehringer IngelheimFor profitNDA2Aug 1, 2014
Boehringer IngelheimFor profitNDAAug 1, 2014
CiplaFor profitMKTGDec 26, 2024
KinapseFor profitMKTGAug 26, 2020
Laurus Labs LtdFor profitMKTGJun 30, 2022
LupinFor profitMKTGJan 6, 2021
MSN LaboratoriesFor profitMKTGJul 7, 2020
Macleods Pharmaceuticals, LtdFor profitMKTGJul 16, 2025
Prinston IncFor profitMKTGJan 20, 2022
Sun PharmaceuticalsFor profitMKTGMar 10, 2023
Syneos HealthFor profitMKTGAug 26, 2020
Zydus Discovery DMCCFor profitMKTGApr 30, 2020
Zydus Discovery DMCCFor profitSYNJul 7, 2022